Toremifene Citrate Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 60 mg
Reference Brands: Fareston(USA)
Category:
Oncology Cancer Care
Toremifene Citrate is available in Tablets
and strengths such as 60 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Toremifene Citrate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Toremifene Citrate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Toremifene, marketed under the brand name Fareston, is an oral selective estrogen receptor modulator (SERM) used primarily in the treatment of advanced or metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown-status tumors. It works by binding to estrogen receptors in breast tissue, blocking estrogen’s effects and thereby slowing the growth of hormone-dependent cancer cells.
Toremifene has demonstrated effectiveness equivalent to tamoxifen in the management of metastatic breast cancer. Beyond its anticancer activity, it has been shown to provide additional benefits, including improving bone mineral density and lipid profiles by positively influencing cholesterol and triglyceride levels. It is also used to alleviate breast pain and has shown superior outcomes compared to tamoxifen for this indication.
In men, toremifene has been reported to improve symptoms of gynecomastia. The medication is taken orally under medical supervision, and ongoing monitoring is recommended to assess treatment efficacy and manage potential side effects. Toremifene’s targeted mechanism and additional metabolic benefits make it a versatile option in hormone therapy for postmenopausal women and selected male patients
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing